Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021

The authors quantified how treatment effects differ between older and younger patients in oncology registration trials . The primary outcome was differential treatment effect by age for progression-free survival and overall survival . Only 7% of end points showed a statistically significant interaction between outcome and age group . There were no changes in the proportion of patients aged 65 years or older over time .

Leave a Reply